ATE301995T1 - Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen - Google Patents

Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen

Info

Publication number
ATE301995T1
ATE301995T1 AT01968030T AT01968030T ATE301995T1 AT E301995 T1 ATE301995 T1 AT E301995T1 AT 01968030 T AT01968030 T AT 01968030T AT 01968030 T AT01968030 T AT 01968030T AT E301995 T1 ATE301995 T1 AT E301995T1
Authority
AT
Austria
Prior art keywords
valproic acid
pain
prevention
derivatives
treatment
Prior art date
Application number
AT01968030T
Other languages
English (en)
Inventor
Mitchell Shirvan
Meir Bialer
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE301995T1 publication Critical patent/ATE301995T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
AT01968030T 2000-08-17 2001-08-17 Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen ATE301995T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22597300P 2000-08-17 2000-08-17
US22597700P 2000-08-17 2000-08-17
PCT/US2001/025919 WO2002013766A2 (en) 2000-08-17 2001-08-17 Valproic acid derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE301995T1 true ATE301995T1 (de) 2005-09-15

Family

ID=26920105

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01968030T ATE301995T1 (de) 2000-08-17 2001-08-17 Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen

Country Status (21)

Country Link
US (3) US20020052418A1 (de)
EP (1) EP1311256B1 (de)
JP (1) JP2004505999A (de)
KR (1) KR100851955B1 (de)
CN (1) CN100462069C (de)
AT (1) ATE301995T1 (de)
AU (1) AU8830801A (de)
CA (1) CA2418455A1 (de)
CZ (1) CZ2004362A3 (de)
DE (1) DE60112766T2 (de)
DK (1) DK1311256T3 (de)
ES (1) ES2245377T3 (de)
HU (1) HUP0401867A2 (de)
IL (2) IL154470A0 (de)
MX (1) MXPA03001458A (de)
NO (1) NO20030724D0 (de)
NZ (1) NZ524687A (de)
PL (1) PL363041A1 (de)
SI (1) SI1311256T1 (de)
WO (1) WO2002013766A2 (de)
ZA (1) ZA200301427B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
EP1243263B1 (de) 2001-03-21 2002-11-27 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
AU2004294714B2 (en) 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
EA013591B1 (ru) 2004-04-16 2010-06-30 Шварц Фарма Аг Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
US20060025477A1 (en) * 2004-07-22 2006-02-02 Artman Linda D Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
PL1781276T3 (pl) 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
ES2326355B1 (es) * 2008-02-25 2010-08-10 Centro Atlantico Del Medicamento, S.A. Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
DK0938304T3 (da) * 1996-08-30 2005-03-14 Nps Pharma Inc Isovaleramid til behandlingen af kramper, epilepsi, hovedpine og spasticitet
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
PL345364A1 (en) * 1998-06-22 2001-12-17 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness
ATE279921T1 (de) * 1999-01-19 2004-11-15 Ortho Mcneil Pharm Inc Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Also Published As

Publication number Publication date
NO20030724L (no) 2003-02-14
JP2004505999A (ja) 2004-02-26
EP1311256A4 (de) 2004-03-24
US8288442B2 (en) 2012-10-16
CN1551762A (zh) 2004-12-01
AU8830801A (en) 2002-02-25
KR100851955B1 (ko) 2008-08-12
EP1311256B1 (de) 2005-08-17
WO2002013766A2 (en) 2002-02-21
MXPA03001458A (es) 2004-05-04
DK1311256T3 (da) 2005-11-28
US20040204495A1 (en) 2004-10-14
US20020052418A1 (en) 2002-05-02
KR20030036691A (ko) 2003-05-09
NZ524687A (en) 2005-01-28
NO20030724D0 (no) 2003-02-14
WO2002013766A3 (en) 2002-06-20
ZA200301427B (en) 2004-02-23
PL363041A1 (en) 2004-11-15
EP1311256A2 (de) 2003-05-21
SI1311256T1 (sl) 2005-12-31
US20090281045A1 (en) 2009-11-12
HUP0401867A2 (hu) 2004-12-28
ES2245377T3 (es) 2006-01-01
DE60112766D1 (de) 2005-09-22
CN100462069C (zh) 2009-02-18
DE60112766T2 (de) 2006-03-30
IL154470A0 (en) 2003-09-17
IL154470A (en) 2010-11-30
CA2418455A1 (en) 2002-02-21
CZ2004362A3 (cs) 2005-01-12

Similar Documents

Publication Publication Date Title
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
NO20061736L (no) Krystallform av epotilon B
EP1765335A4 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
DE602004016841D1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE602004025001D1 (de) Verbindungen zur behandlung von neuropathischen schmerzen und migräne
RS20060049A (en) Novel n-substituted indolyl-3-glycoxylic acid amides, use thereof as a medicament and method for the production thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311256

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee